Bone Biologics Statistics
Total Valuation
Bone Biologics has a market cap or net worth of $2.23 million. The enterprise value is -$2.32 million.
Important Dates
The last earnings date was Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Bone Biologics has 1.80 million shares outstanding. The number of shares has increased by 316.40% in one year.
| Current Share Class | 1.80M |
| Shares Outstanding | 1.80M |
| Shares Change (YoY) | +316.40% |
| Shares Change (QoQ) | -0.38% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 0.68% |
| Float | 1.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.47 |
| P/TBV Ratio | 0.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.09
| Current Ratio | 16.09 |
| Quick Ratio | 14.67 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -75.40% and return on invested capital (ROIC) is -49.49%.
| Return on Equity (ROE) | -75.40% |
| Return on Assets (ROA) | -46.08% |
| Return on Invested Capital (ROIC) | -49.49% |
| Return on Capital Employed (ROCE) | -64.27% |
| Weighted Average Cost of Capital (WACC) | 7.15% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.43M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.17% in the last 52 weeks. The beta is 0.53, so Bone Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | -72.17% |
| 50-Day Moving Average | 1.26 |
| 200-Day Moving Average | 1.74 |
| Relative Strength Index (RSI) | 40.82 |
| Average Volume (20 Days) | 9,280 |
Short Selling Information
The latest short interest is 10,427, so 0.58% of the outstanding shares have been sold short.
| Short Interest | 10,427 |
| Short Previous Month | 7,180 |
| Short % of Shares Out | 0.58% |
| Short % of Float | 0.58% |
| Short Ratio (days to cover) | 0.93 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.00M |
| Pretax Income | -2.86M |
| Net Income | -2.86M |
| EBITDA | n/a |
| EBIT | -3.00M |
| Earnings Per Share (EPS) | -$1.92 |
Full Income StatementBalance Sheet
The company has $4.53 million in cash and n/a in debt, with a net cash position of $4.53 million or $2.52 per share.
| Cash & Cash Equivalents | 4.53M |
| Total Debt | n/a |
| Net Cash | 4.53M |
| Net Cash Per Share | $2.52 |
| Equity (Book Value) | 4.67M |
| Book Value Per Share | 2.60 |
| Working Capital | 4.67M |
Full Balance SheetCash Flow
| Operating Cash Flow | -2.57M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -2.57M |
| FCF Per Share | -$1.43 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
